Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Press Releases

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

ALPHARETTA, Ga., Aug. 08, 2024 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that management will present a corporate update at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference which will be available on demand on Thursday, August 15, 2024, at 7:00 a.m. ET. Victor Chong, MD, MBA, Chief Medical Officer, will also participate in a panel discussion on the Evolving Therapeutic Landscape of AMD.

A link to the live and archived webcast presentation may be accessed on the Clearside website under the Investors section: Events and Presentations.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com and follow us on LinkedIn and X.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

Related Articles
TheFlyClearside Biomedical’s partner signed new collaboration agreement with Santen
TheFlyClearside Biomedical appoints Gibney as new Chair of board of directors
TheFlyClearside Biomedical announces multiple presentations delivered at 2024 AAO
Go Ad-Free with Our App